SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema. In each of these areas, SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the SkinBiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and out-license its programmes at the proof of concept. SkinBioTherapeutics plc was admitted to London's AIM on 5th April 2017, raising £4.5m.